ClinicalTrials.gg
CompletedNCT06367036Updated Apr 16, 2024

Effect of Hypericum Perforatum Oil on Ecchymosis and Pain

An interventional study of Topical hypericum perforatum oil intervention in Pain and Ecchymosis, sponsored by Uskudar University. Completed at 1 site in Turkey. Per ClinicalTrials.gov, last updated 2024-04-16.

Sponsored by Uskudar University · Not applicable, Interventional, and Prevention

From the registry’s dates

  • Registered 2 years 3 months after the study started (first participant enrolled Jan 2022, registered Apr 2024).
Phase
Not applicable
Study type
Interventional
Enrollment
160
Allocation
Non-randomized
Sex
All
01

Study summary

Low molecular weight heparin is a drug with anticoagulant and antithrombotic effects. This drug is frequently administered subcutaneously to patients by nurses. Complications such as pain, ecchymosis and hematoma may commonly occur at the injection site. This study investigated the effect of Hypericum Perforatum oil in preventing pain and ecchymosis after subcutaneous injection low molecular weight heparin. This quasi-experimental and single blinded study was conducted with 160 patients in a coronary intensive care unit. The researcher nurse applied 5-6 drops of Hypericum Perforatum oil to one arm of the patients 2 hours before the injection. The other arm of the patient was considered as the control arm. A total of 320 injections were administered. The evaluation of the injection sites was performed by two other researchers at 48th hours. The data were analyzed using Wilcoxon and McNemar test.

02

Conditions studied

  • Pain
  • Ecchymosis

Browse trials for

Keywords

  • Hypericum Perforatum oil
  • low molecular weight heparin
  • subcutaneous injection
  • ecchymosis
  • pain
03

In context

Pain

10,054 studies on the registry are indexed under Pain; 1,649 are open to participants now.

This study's enrollment of 160 is above the median of 66 across 8,493 interventional studies indexed under Pain.

Browse Pain studies →

Lead sponsor

Uskudar University is the lead sponsor of 170 studies on the registry; 36 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Over 18 years of age
  • Normal value,
  • Normal (INR) and prothrombin time (PTZ) values,
  • No infection, scar tissue or incision in the lateral upper arm

Exclusion criteria

Exclusion Criteria:

  • Pregnancy
  • Administration of haemodialysis
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
Single (Investigator)
Enrollment
160 participants (actual)

Study arms

  • Experimental
    Hypericum Perforatum Oil group

    This research is a self-controlled study. One injected arm of the patient will be assigned to the intervention group and the other arm to the control group. İn the experimental arm, the research nurse working in the Coronary Intensive Care unit (CICU) applied 5-6 drops of HP oil on one arm of the patient with a patting motion 2 hours before the injection. The area was left open for the oil to be absorbed. Only this nurse who administered the injection knows on which arm the oil was applied. The assessment of ecchymosis and pain at the injection site was performed by two other investigators at the 48th hour of the injection (Single blind).

    Other: Topical hypericum perforatum oil intervention

  • No intervention
    Control group

    This research is a self-controlled study. One injected arm of the patient will be assigned to the intervention group and the other arm to the control group.In the control arm, no treatment was performed before injection.The assessment of ecchymosis and pain at the injection site was performed by two other investigators at the 48th hour of the injection (Single blind).

Interventions

  • OtherTopical hypericum perforatum oil intervention

    The research nurse working in the CICU applied 5-6 drops of hypericum perforatum oil on one arm of the patient with a patting motion 2 hours before the injection. The area was left open for the oil to be absorbed. Only this nurse who administered the injection knows on which arm the oil was applied.

06

What researchers measure

Primary outcomes

  1. Pain point

    The patient's pain was evaluated with Visual Analogue Scale (VAS) 48 hours after the injection. Visual Analogue Scale is a reliable pain assessment scale to determine the pain felt by patients at the injection site. The VAS is a self-report scale consisting of a horizontal line (10 cm long) with anchor points "no pain" and "worst possible pain". The patient is asked to mark the place on this line that best describes the intensity of pain. A marking of "0" means "no pain". Marking "10" means "'intolerable pain". In this way, the patient scores his/her pain between 1-10.

    Time frame: 48 hours after injection

  2. Ecchymosis

    Ecchymosis was evaluated at 48th hours after injection in the study. A transparent ruler that allows millimetric measurement was used to measure the ecchymosis at the injection site. The discoloration at the injection site was measured in millimeter. Ecchymosis was defined as an area of discolored skin of more than 2 mm appearing 48th hours after administration. The maximum horizontal extent (diameter) of the bruise was recorded regardless of whether the bruise was regular or uneven in shape at the time of measurement. According to previous studies, bruise size was analyzed according to 3 categories: no bruise (0-1 mm), small bruise (2-5 mm) and large bruise (\>5 mm). In our study, bruises \>2 mm in size was accepted as ecchymosis.

    Time frame: 48 hours after injection

07

Study locations

1 site
  • Hatice Demirdağ
    Üsküdar, İstanbul 34672, Turkey
08

References and documents

Individual participant data

Plan to share: No — It will be shared if necessary and requested.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06367036
Lead sponsor
Uskudar University
Responsible party
HATİCE DEMİRDAĞ (Assistant Proffessor, Uskudar University) — Principal investigator
First posted
Apr 16, 2024
Start date
Jan 2, 2022
Primary completion
Dec 29, 2022
Completion
Jun 15, 2023
Last update
Apr 16, 2024

Study contacts

Nurcan UYSAL, Associate Professor
study chair · Üsküdar University
Zehra KAMBER
study chair · Siyami Ersek Thoracic and Cardiovascular Surgery Education Research Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion